BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9224298)

  • 1. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
    Pariente JL; Bordenave L; Michel P; Latapie MJ; Ducassou D; Le Guillou M
    J Urol; 1997 Aug; 158(2):338-41. PubMed ID: 9224298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.
    Pariente JL; Bordenave L; Jacob F; Gobinet A; Leger F; Ferriere JM; Le Guillou M
    J Urol; 2000 Apr; 163(4):1116-9. PubMed ID: 10737478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
    J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
    Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical usefulness of urinary determinations of cytokeratin 19 fragment (CYFRA 21-1) in urothelial tumor].
    Takeuchi S; Saitoh H; Yoshida K; Satake I; Tari K
    Hinyokika Kiyo; 1995 Aug; 41(8):589-92. PubMed ID: 7572437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
    Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
    Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
    Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
    Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
    Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
    Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular fibronectin in patients with transitional cell carcinoma of the bladder.
    Hegele A; Heidenreich A; Varga Z; von Knobloch R; Olbert P; Kropf J; Hofmann R
    Urol Res; 2003 Feb; 30(6):363-6. PubMed ID: 12599015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
    Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
    Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.